Boothbay Fund Management’s Definium Therapeutics DFTX Stock Holding History

Boothbay Fund Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$266K	Buy	+14,096	New	+$239K	﹤0.01%	1659
2025 Q4	–	Sell	-67,984	Closed	-$802K	–	2213
2025 Q3	$802K	Buy	67,984 +50,000	+278%	+$466K	0.01%	925
2025 Q2	$117K	Hold	17,984	–	–	﹤0.01%	1300
2025 Q1	$105K	Hold	17,984	–	–	﹤0.01%	1225
2024 Q4	$125K	Buy	17,984 +210	+1%	+$1.45K	﹤0.01%	1256
2024 Q3	$101K	Sell	17,774 -28,447	-62%	-$198K	﹤0.01%	1457
2024 Q2	$333K	Sell	46,221 -38,403	-45%	-$336K	0.01%	1127
2024 Q1	$795K	Sell	84,624 -62,036	-42%	-$354K	0.02%	831
2023 Q4	$537K	Buy	+146,660	New	+$442K	0.01%	967
2022 Q2	–	Sell	-736	Closed	-$12K	–	2509
2022 Q1	$12K	Hold	736	–	–	﹤0.01%	2233
2021 Q4	$15K	Buy	+736	New	+$23.5K	﹤0.01%	1801

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boothbay Fund Management's DFTX Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 14,096 shares worth $266K. The stake represents ﹤0.01% of the portfolio and ranks #1659 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in DFTX as recently as Q3 2025.

Boothbay Fund Management first reported a position in DFTX in Q4 2021 and has held it in 11 quarters since. The position peaked at $802K in Q3 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Boothbay Fund Management held 14,096 shares of Definium Therapeutics worth $266K as of Q1 2026.
Definium Therapeutics was a new Boothbay Fund Management position in Q1 2026.
Definium Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1659 holding.
Boothbay Fund Management first reported a position in Definium Therapeutics in Q4 2021 and has held it in 11 quarters since.
Boothbay Fund Management's Definium Therapeutics position peaked at $802K in Q3 2025.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.